Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial

Published:August 24, 2021DOI:https://doi.org/10.1016/j.jiac.2021.08.021

      Abstract

      Introduction

      Ivermectin is an antiparasitic drug which has in-vitro efficacy in reducing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) viral load. Hence, Ivermectin is under investigation as a repurposed agent for treating COVID-19.

      Methods

      In this pilot, double blind, randomized controlled trial, hospitalized patients with mild-to-moderate COVID-19 were assigned to a single oral administration of an elixir formulation of Ivermectin at either 24 mg or 12 mg dose, or placebo in a 1:1:1 ratio. The co-primary outcomes were conversion of RT-PCR to negative result and the decline of viral load at day 5 of enrolment. Safety outcomes included total and serious adverse events. The primary outcomes were assessed in patients who had positive RT-PCR at enrolment (modified intention-to-treat population). Safety outcomes were assessed in all patients who received the intervention (intention-to-treat population).

      Results

      Among the 157 patients randomized, 125 were included in modified intention-to-treat analysis. 40 patients each were assigned to Ivermectin 24 mg and 12 mg, and 45 patients to placebo. The RT-PCR negativity at day 5 was higher in the two Ivermectin arms but failed to attain statistical significance (Ivermectin 24 mg, 47.5%; 12 mg arm, 35.0%; and placebo arm, 31.1%; p-value = 0.30). The decline of viral load at day 5 was similar in each arm. No serious adverse events occurred.

      Conclusions

      In patients with mild and moderate COVID-19, a single oral administration of Ivermectin did not significantly increase either the negativity of RT-PCR or decline in viral load at day 5 of enrolment compared with placebo.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Journal of Infection and Chemotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Dong E.
        • Du H.
        • Gardner L.
        An interactive web-based dashboard to track COVID-19 in real time.
        Lancet Infect Dis. 2020 May 1; 20: 533-534
        • Omura S.
        • Crump A.
        Ivermectin: panacea for resource-poor communities?.
        Trends Parasitol. 2014 Sep; 30: 445-455
        • Wagstaff K.M.
        • Sivakumaran H.
        • Heaton S.M.
        • Harrich D.
        • Jans D.A.
        Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus.
        Biochem J. 2012 May 1; 443: 851-856
        • Mastrangelo E.
        • Pezzullo M.
        • De Burghgraeve T.
        • Kaptein S.
        • Pastorino B.
        • Dallmeier K.
        • et al.
        Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug.
        J Antimicrob Chemother. 2012 Aug; 67: 1884-1894
        • Yang S.N.Y.
        • Atkinson S.C.
        • Wang C.
        • Lee A.
        • Bogoyevitch M.A.
        • Borg N.A.
        • et al.
        The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer.
        Antivir Res. 2020; 177: 104760
        • Caly L.
        • Druce J.D.
        • Catton M.G.
        • Jans D.A.
        • Wagstaff K.M.
        The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
        Antivir Res. 2020; 178: 104787
        • Chiu S.H.
        • Taub R.
        • Sestokas E.
        • Lu A.Y.
        • Jacob T.A.
        Comparative in vivo and in vitro metabolism of ivermectin in steers, sheep, swine, and rat.
        Drug Metab Rev. 1987; 18: 289-302
        • Lifschitz A.
        • Virkel G.
        • Sallovitz J.
        • Sutra J.F.
        • Galtier P.
        • Alvinerie M.
        • et al.
        Comparative distribution of ivermectin and doramectin to parasite location tissues in cattle.
        Vet Parasitol. 2000 Feb 1; 87: 327-338
        • Ahmed S.
        • Karim M.M.
        • Ross A.G.
        • Hossain M.S.
        • Clemens J.D.
        • Sumiya M.K.
        • et al.
        A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness.
        Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2021 Feb; 103: 214-216
        • Samaha A.A.
        • Mouawia H.
        • Fawaz M.
        • Hassan H.
        • Salami A.
        • Bazzal A.A.
        • et al.
        Effects of a single dose of ivermectin on viral and clinical outcomes in asymptomatic SARS-CoV-2 infected subjects: a pilot clinical trial in Lebanon.
        Viruses. 2021 May 26; 13: 989
        • López-Medina E.
        • López P.
        • Hurtado I.C.
        • Dávalos D.M.
        • Ramirez O.
        • Martínez E.
        • et al.
        Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial.
        J Am Med Assoc. 2021 Apr 13; 325: 1426-1435
        • Chaccour C.
        • Casellas A.
        • Matteo A.B.-D.
        • Pineda I.
        • Fernandez-Montero A.
        • Ruiz-Castillo P.
        • et al.
        The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial.
        EClinicalMedicine. 2021 Feb 1; ([Internet]) ([cited 2021 Jun 21];32. Available from:)
        • de Castro Jr., C.G.
        • Gregianin L.J.
        • Burger J.A.
        Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection.
        Leuk Lymphoma. 2020 Aug 23; 61: 2536-2537
      1. Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. Pharmacokinet Pharmacodyn. :12.

        • Borghesi A.
        • Maroldi R.
        COVID-19 outbreak in Italy: experimental chest X-ray scoring system for quantifying and monitoring disease progression.
        Radiol Med. 2020 May 1; : 1-5
        • Lespine A.
        • Alvinerie M.
        • Sutra J.-F.
        • Pors I.
        • Chartier C.
        Influence of the route of administration on efficacy and tissue distribution of ivermectin in goat.
        Vet Parasitol. 2005 Mar 31; 128: 251-260
        • WHO R&D Blueprint novel Coronavirus
        COVID-19 therapeutic trial synopsis.
        ([Internet]) World Health Organization, 2020 ([cited 2020 Oct 29]. Available from:)
        • Peña‐Silva R.
        • Duffull S.B.
        • Steer A.C.
        • Jaramillo‐Rincon S.X.
        • Gwee A.
        • Zhu X.
        Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID‐19.
        Br J Clin Pharmacol. 2020 Jul 17; (bcp): 14476
        • Shu E.N.
        • Onwujekwe E.O.
        • Okonkwo P.O.
        Do alcoholic beverages enhance availability of ivermectin?.
        Eur J Clin Pharmacol. 2000 Aug; 56: 437-438
        • Krause R.M.
        • Buisson B.
        • Bertrand S.
        • Corringer P.J.
        • Galzi J.L.
        • Changeux J.P.
        • et al.
        Ivermectin: a positive allosteric effector of the alpha7 neuronal nicotinic acetylcholine receptor.
        Mol Pharmacol. 1998 Feb; 53: 283-294
        • Changeux J.-P.
        • Amoura Z.
        • Rey F.A.
        • Miyara M.
        A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications.
        C R Biol. 2020 Jun 5; 343: 33-39
        • Podder C.
        • Chowdhury N.
        • Sina M.
        • Haque W.
        Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study.
        IMC J Med Sci. 2020 Sep 3; : 14
        • Rao S.N.
        • Manissero D.
        • Steele V.R.
        • Pareja J.
        A narrative systematic review of the clinical utility of cycle threshold values in the context of COVID-19.
        Infect Dis Ther. 2020 Jul 28; : 1-14
        • Rajter J.C.
        • Sherman M.S.
        • Fatteh N.
        • Vogel F.
        • Sacks J.
        • Rajter J.-J.
        Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019.
        Chest. 2020 Oct; (S0012369220348984)
        • Heidary F.
        • Gharebaghi R.
        Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen.
        J Antibiot (Tokyo). 2020 Sep; 73: 593-602
        • Rahman M.A.
        • Iqbal S.A.
        • Islam M.A.
        • Niaz M.K.
        • Hussain T.
        • Siddiquee T.H.
        Comparison of viral clearance between ivermectin with doxycycline and hydroxychloroquine with azithromycin in COVID-19 patients.
        J Bangladesh Coll Phys Surg. 2020 Jun 12; : 5-9
        • Zhou F.
        • Yu T.
        • Du R.
        • Fan G.
        • Liu Y.
        • Liu Z.
        • et al.
        Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
        Lancet. 2020 Mar 28; 395 (10229): 1054-1062
        • Wolff D.
        • Nee S.
        • Hickey N.S.
        • Marschollek M.
        Risk factors for Covid-19 severity and fatality: a structured literature review.
        Infection. 2020 Aug 28; : 1-14